A Clinical Study to Evaluate Efficacy and Safety of HSK21542 for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia

Postoperative Analgesia Clinical Trial

Official title:

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04738357
• Other study ID #: HSK21542-301
• Status: Completed
• Phase: Phase 3
• Start date: March 24, 2021
• Est. completion date: September 30, 2021

Study information

• Verified date: May 2022
• Source: Haisco Pharmaceutical Group Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multi-center, randomized, double-blind, placebo-controlled study. A total of 276 subjects undergoing elective laparoscopic surgery under general anesthesia are planned to be enrolled and randomized into 2 groups, i.e., the HSK21542 group (138 subjects) and the placebo group (138 subjects).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 276
• Est. completion date: September 30, 2021
• Est. primary completion date: July 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. 18 = age = 70 years old, with no gender requirement;

2. American Society of Anesthesiologists (ASA) Class I-II;

3. BMI = 18 kg/m2 and = 40 kg/m2;

4. Subjects undergoing elective laparoscopic surgery under general anesthesia with an expected surgery duration of 1-5 h (inclusive);

5. Agree to participate in this trial and voluntarily sign the informed consent form;

Exclusion Criteria:

1. With a history of allergy to opioids, such as urticaria, or allergic to intraoperative anesthetics as prescribed in the protocol;

2. Patients with history or evidence of any of the following diseases prior to screening:

1. History of cardiovascular diseases: uncontrolled hypertension (systolic blood pressure [SBP] = 170 mmHg and/or diastolic blood pressure [DBP] = 105 mmHg without treatment, or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment), aneurysm, severe arrhythmia, heart failure, Adams-stokes syndrome, New York Heart Association (NYHA) Class = III, severe superior vena cava syndrome, pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medical treatment, II-III degree atrioventricular block (excluding patients with pacemakers);

2. History of respiratory system disorders: severe chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, severe airway stenosis, throat mass, history of tracheoesophageal fistula or airway tear, severe respiratory infection within 2 weeks prior to screening;

3. History of neurological and psychiatric disorders: craniocerebral injury, convulsions, intracranial hypertension, cerebral aneurysms, history of cerebrovascular accidents; schizophrenia, mania, insanity, long-term use of psychotropic drugs, and history of cognitive dysfunction; history of depression, anxiety, and epilepsy, etc.;

4. Have undergone any major surgery within 3 months prior to screening, which may affect postoperative pain assessment as judged by the investigator;

3. In receipt of any one of the following medications or treatments at screening:

1. A time between the last use of opioid and non-opioid (such as paracetamol, aspirin [daily dose > 100 mg], indometacin, diclofenac, parecoxib sodium, and other non-steroidal anti-inflammatory drugs) analgesics and randomization of shorter than 5 half-lives of the drug or the duration of response (whichever is longer);

2. Longer than 10 days of continuous use of opioid analgesics for any reason within 3 months prior to screening;

3. Use of drugs with unknown half-life that affect the analgesic effect within 14 days before randomization, or the last use of drugs that affect the analgesic effect is within 5 half-lives (as per the packaging insert of the drug) apart from randomization, such drugs include but are not limited to: sedative-hypnotics (benzodiazepines [triazolam, diazepam, midazolam, etc.], non-benzodiazepines [zolpidem, zopiclone, zaleplon, etc.]), sedative anesthetics (sevoflurane, anesthetic ether, nitrous oxide, thiopental sodium, ketamine, etomidate, etc.), glucocorticoids (dexamethasone hydrochloride, methylprednisolone, etc.), antiepileptics (carbamazepine, sodium valproate, etc.), anxiolytics (chlordiazepoxide, diazepam, etc.), antidepressants (imipramine, amitriptyline, etc.), and Chinese herbal medicines or Chinese patent medicines with analgesic and sedative effects;

4. Expected to receive any anti-tumor drug or therapy from 14 days prior to randomization to the end of the follow-up period, including but not limited to chemotherapy drugs, targeted drugs, and Chinese herbal medicines;

5. A time between randomization and the last use of diuretics and compound drugs containing diuretics of shorter than 5 half-lives of the drug or the duration of response (whichever is longer);

4. The laboratory parameters measured at screening period reach one of the following

criteria:

1. WBC < 3.0 × 109/L;

2. Platelet count < 80 × 109/L;

3. Hemoglobin < 70 g/L;

4. Prothrombin time > 1.5 × ULN;

5. Activated partial thromboplastin time > 1.5 × ULN;

6. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2 × ULN;

7. Total bilirubin > 1.5 × ULN;

8. Blood creatinine > 1.5 × ULN;

9. Fasting blood glucose = 11.1 mmol/L;

5. Positive for hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody at screening;

6. History of medication or drug abuse and/or alcohol abuse within 3 months prior to screening (alcohol abuse is defined as an average of > 2 units of alcohol consumed per day [1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor with 40% alcohol, or 150 mL of wine]);

7. History of blood donation or blood loss of = 400 mL within 3 months prior to screening;

8. Have participated in other clinical trials within 3 months prior to screening (defined as having received investigational product or placebo);

9. Pregnant or breastfeeding females; women of child-bearing potential or men who are unwilling to use contraception during the trial; or subjects who are planning pregnancy within 3 months after the completion of the trial (including male subjects);

10. Subject judged by the investigator to have any other factors unsuitable for involvement in the study.

Related Conditions & MeSH terms

• Postoperative Analgesia

Intervention

Drug:
• HSK21542
HSK21542:1 µg/kg
• Placebo
Placebo

Locations

Country	Name	City	State
China	Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou

Sponsors (1)

Lead Sponsor	Collaborator
Haisco Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sum of Pain Intensity Differences (SPID)	The time-weighted SPID at rest within 0-24 h after the first postoperative administration in each group	Frome administration until 24 hours after administration
Secondary	Sum of Pain Intensity Differences (SPID)	The time-weighted SPID at rest within 0-12 h after the first postoperative administration in each group	Frome administration until 12 hours after administration
Secondary	Use of remedial analgesics	Cumulative used amount of remedial analgesics (morphine injection, mg) within 0-12 h or 0-24 h after the first postoperative administration in each group, percentage of subjects not using remedial analgesics, and start time of remedial analgesic use	Frome administration until 24 hours after administration
Secondary	Pain Intensity Differences(PID)	The PID at rest at each scoring time point after the first postoperative administration in each group	Frome administration until 24 hours after administration
Secondary	The proportion of subjects with a NRS of = 3	The ratio of subjects with NRS score = 3 at 12 h or 24 h after the first postoperative administration in each group	Frome administration until 24 hours after administration
Secondary	Duration of analgesia	The duration of analgesia after the first postoperative administration in each group	Frome administration until 24 hours after administration
Secondary	Satisfaction scores on postoperative analgesia	Subject satisfaction score and investigator satisfaction score on postoperative analgesia at 24 h after the first postoperative administration in each group	Frome administration until 24 hours after administration
Secondary	The incidence and severity of AEs	Adverse event/serious adverse event	from signing the informed consent form to the follow-up period (D8 ± 1 postoperative).
Secondary	Cumulative used amount and ratio of antiemetics	Cumulative used amount and ratio of antiemetics within 0-24 h after the first postoperative administration in each group	Frome administration until 24 hours after administration